Tumor cell clearance reimagined.
Our mission is to discover, translate, and deliver pioneering curative cell therapies that incorporate multiple forms of tumor clearance into single T cells.
CERs explained
Our technology aims to integrate anti-tumor capabilities of both the innate and adaptive immune systems into a single T cell.
› Exploiting a Natural Immune Process
The CER platform
We are advancing a CER T-cell platform that potentially offers novel approaches for the treatment of both hematologic malignancies and solid tumors.
› Therapeutic Potential of Our Platform
Join the quest
Our culture is mission-and innovation-driven towards bringing improved treatment options to patients. We are looking for talented and motivated individuals to join us in our quest.
› Careers at CERo
A differentiated mechanism of action for solid tumors
Check out pre-clinical data on CER T cell activity in NSCLC presented at the Society of Immunotherapy of Cancer (SITC) annual meeting.
› Read articleNews and events
Mar 07, 2024
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML PatientsFeb 14, 2024
Phoenix Biotech Acquisition Corp. and Cero Therapeutics Holdings, Inc. Announce Close of Business CombinationJun 05, 2023
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics